Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 24Urinary Bladder Neoplasms 5Neoplasms 2Urothelial Bladder Cancer 1Urologic Neoplasms 1Urinary Bladder Diseases 1Stomach Neoplasms 1Recurrence 1Prostate cancer, familial 1Parotid Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Lung Neoplasms 1Genetic Predisposition to Disease 1Driving Under the Influence 1Disease Progression 1Disease 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Lenalidomide 4Gemcitabine 4Dexamethasone 4Cyclophosphamide 4Bortezomib 4Nivolumab 3Cisplatin 3Carboplatin 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2pomalidomide 2pembrolizumab 2liposomal doxorubicin 2fludarabine 2durvalumab 2capivasertib 2Radiosurgery 2Paclitaxel 2Doxorubicin 2Bevacizumab 2Anthropogenic Effects 2venetoclax 1umbralisib 1ublituximab 1tremelimumab 1tivozanib 1ricolinostat 1regorafenib 1pazopanib 1niraparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × Multiparametric Magnetic Resonance Imaging × Clear all
NCT04692675 2026-05-06

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase NA Recruiting
508 enrolled
Genitourinary

Prostatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡